Pemetrexed
- Atc Codes:L01BA04
- CAS Codes:150399-23-8#137281-23-3
- PHARMGKB ID:150399-23-8#137281-23-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Alimta; Belgium: Alimta; Bulgaria: Alimta; Czech Republic: Alimta; Denmark: Alimta; Estonia: Alimta; Finland: Alimta; France: Alimta; Germany: Alimta; Greece: Alimta; Hungary: Alimta; Ireland: Alimta; Italy: Alimta; Latvia: Alimta; Lithuania: Alimta; Malta: Alimta; Netherlands: Alimta; Poland: Alimta; Portugal: Alimta; Romania: Alimta; Slovakia: Alimta; Slovenia: Alimta; Spain: Alimta; Sweden: Alimta; UK: Alimta.
North America
Canada: Alimta; USA: Alimta.
Latin America
Argentina: Alimta; Brazil: Alimta; Mexico: Alimta.
Asia
Japan: Alimta.
Drug combinations
Chemistry
Pemetrexed Disodium: C~20~H~19~N~5~Na~2~O~6~. Mw: 471.37. (1) L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt; (2) Disodium N-[p-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamate. CAS-150399-23-8; CAS-137281-23-3 (pemetrexed)(2004).
Pharmacologic Category
Antineoplastic Agents; Antimetabolites. (ATC-Code: L01BA04).
Mechanism of action
Inhibits thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase, and aminoimidazole carboxamide ribonucleotide formyltransferase, enzymes involved in folate metabolism and DNA synthesis, resulting in inhibition of purine and thymidine nucleotide and protein synthesis.
Therapeutic use
Treatment of malignant pleural mesothelioma. Treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer.
Pregnancy and lactiation implications
Adverse events observed in animal reproduction studies. There are no adequate, well-controlled trials in pregnant women. Use not recommended during lactation.
Unlabeled use
Treatment of bladder cancer.
Contraindications
Severe hypersensitivity to pemetrexed or any component of the formulation.
Warnings and precautions
Hazardous agent. Use may cause anemia, neutropenia, thrombocytopenia and/or pancytopenia. Cutaneous reactions may occur. Gastrointestinal toxicity may occur. Use caution with hepatic impairment not due to metastases. Decreased renal function results in increased toxicity. Use not recommended if CrCl <45 mL/minute. Use caution in patients receiving concurrent nephrotoxins (may result in delayed pemetrexed clearance). NSAIDs may reduce clearance of pemetrexed.